Strengthening the financial base through funding from capital markets and investors
First written in FY2019. 19 of 30 entries say "Advanced", first in FY2020-Q1. Latest entry: FY2026.
1 other company's latest entry also says "Other".
- FY2026No proceeds from share issuance for the full year eitherAnnual report
「Funds provided by financing activities amounted to nil, compared with proceeds of ¥41.250 million in the previous fiscal year.」
As in the previous interim period, the Company generated no funds from financing activities during the fiscal year, and no financing through share issuance or other means took place during the full year. - FY2026-H1No proceeds from share issuance during the interim periodAnnual report
「There were no funds used or provided by financing activities during the interim accounting period (¥41.250 million was provided in the same period of the previous year).」
Unlike the previous trend of continuing to raise funds from the capital markets, no funds were provided by financing activities during the interim accounting period. - 2026-03-11OtherEarnings
「The company has secured sufficient funding for research and development activities through 2028.」
The company stated that it had secured the funding required for research and development activities through 2028. - FY2025RestatedAnnual report
「Cash provided by financing activities during the fiscal year was ¥41.250 million (compared with ¥78.966 million provided in the previous fiscal year). This was attributable to proceeds from the issuance of shares upon the exercise of stock acquisition rights.」
Fundraising through the exercise of stock acquisition rights continues, although the amount raised has declined from the previous fiscal year. - FY2025-H1AdvancedAnnual report
「Cash provided by financing activities during the interim accounting period was ¥41.250 million (compared with ¥62.800 million provided in the same period of the previous year). This was attributable to ¥41.250 million in proceeds from the issuance of shares.」
The company raised ¥41.250 million through the issuance of shares. Although the amount declined from the same period of the previous year, fundraising through the capital markets continues. - FY2024AdvancedAnnual report
「Cash provided by financing activities was ¥78.966 million (compared with ¥202.602 million provided in the previous fiscal year). This was mainly attributable to proceeds from the issuance of shares upon the exercise of stock acquisition rights.」
The company raised ¥78.966 million through the issuance of shares upon the exercise of stock acquisition rights, continuing to raise funds through the capital markets. - FY2024-Q3AdvancedAnnual report
「Total net assets at the end of the third quarter of the current fiscal year amounted to ¥9,371.096 million, a decrease of ¥999.363 million from the end of the previous fiscal year. This was mainly due to the recognition of a quarterly net loss of ¥1,519 million, partly offset by increases of ¥202.319 million each in capital stock and capital surplus resulting from the exercise of stock acquisition rights and the issuance of restricted shares as stock-based compensation to officers.」
The exercise of stock acquisition rights and the issuance of restricted shares resulted in an increase of ¥202.319 million each in capital stock and capital surplus. - FY2024-Q2AdvancedAnnual report
「Funds provided by financing activities during the six-month period amounted to ¥62.8 million, compared with proceeds of ¥99.349 million in the same period of the previous year. This was mainly attributable to proceeds of ¥63.332 million from the issuance of shares.」
The company raised ¥63.332 million through the issuance of shares during the six-month period, indicating that fundraising through the capital markets continued. - FY2024-Q1AdvancedAnnual report
「This was mainly due to the recognition of a quarterly net loss of ¥467.145 million, partly offset by increases of ¥35.905 million each in capital stock and capital surplus resulting from the exercise of stock acquisition rights.」
During the first quarter, the exercise of stock acquisition rights increased capital stock and capital surplus by ¥35.905 million each, indicating that fundraising through the capital markets continued. - FY2023AdvancedAnnual report
「Funds provided by financing activities amounted to ¥202.602 million, compared with proceeds of ¥112.859 million in the previous fiscal year. This was mainly attributable to proceeds from the issuance of shares through the exercise of stock acquisition rights.」
Funds generated through financing activities increased from ¥112.859 million in the previous fiscal year to ¥202.602 million, mainly through the issuance of shares upon the exercise of stock acquisition rights. - FY2023-Q3AdvancedAnnual report
「1 February 2023–30 April 2023 (Note) 651,400 60,647,000 19,655 159,571 19,655 8,758,355 (Note) Increase due to the exercise of stock acquisition rights.」
During the third quarter, the exercise of stock acquisition rights resulted in the issuance of 651,400 shares and an increase of ¥19.655 million each in capital stock and the capital reserve. - FY2023-Q2AdvancedAnnual report
「Funds provided by financing activities during the six-month period amounted to ¥99.349 million, compared with proceeds of ¥92.784 million in the same period of the previous year. This was mainly attributable to proceeds of ¥100.996 million from the issuance of shares.」
The company raised ¥100.996 million through the issuance of shares during the six-month period, indicating that fundraising through the capital markets continued. - FY2023-Q1AdvancedAnnual report
「As a result, total assets amounted to ¥9,303.766 million, a decrease of ¥293.606 million from the end of the previous fiscal year. This was mainly due to the recognition of a quarterly net loss of ¥513.501 million, partly offset by increases of ¥61.051 million each in capital stock and capital surplus resulting from the exercise of stock acquisition rights.」
During the first quarter, the exercise of stock acquisition rights increased capital stock and capital surplus by ¥61.051 million each, indicating that fundraising through the capital markets is continuing. - FY2022AdvancedAnnual report
「Funds provided by financing activities amounted to ¥112.859 million, compared with proceeds of ¥109.317 million in the previous fiscal year. This was mainly attributable to proceeds from the issuance of shares through the exercise of stock acquisition rights.」
The company generated ¥112.859 million in financing funds during the fiscal year, mainly through the exercise of stock acquisition rights, indicating that fundraising through the capital markets is continuing. - FY2022-Q3AdvancedAnnual report
「1 February 2022–30 April 2022 (Note) 30,000 59,342,700 4,500 66,876 4,500 10,610,732 (Note) Increase due to the exercise of stock acquisition rights.」
During the third quarter, the exercise of stock acquisition rights resulted in the issuance of 30,000 shares and an increase of ¥4.5 million each in capital stock and the capital reserve. Fundraising through the exercise of stock acquisition rights is continuing. - FY2022-Q2AdvancedAnnual report
「Funds provided by financing activities during the six-month period amounted to ¥92.784 million, compared with proceeds of ¥95.568 million in the same period of the previous year. This was mainly attributable to proceeds of ¥94.305 million from the issuance of shares.」
The company generated ¥92.784 million in financing funds during the six-month period, mainly through the issuance of shares, indicating that funding through the capital markets is continuing. - FY2022-Q1AdvancedAnnual report
「1 August 2021–31 October 2021 (Note) 112,500 58,964,100 15,515 47,939 15,515 10,515,922 (Note) Increase due to the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in the issuance of 112,500 shares and an increase of ¥15.515 million each in capital stock and the capital reserve. - FY2021AdvancedAnnual report
「Funds provided by financing activities during the fiscal year amounted to ¥109.317 million, compared with proceeds of ¥7,757.140 million in the previous fiscal year. This was mainly attributable to proceeds from the issuance of shares through the exercise of stock acquisition rights.」
The company secured ¥109.317 million in financing funds during the fiscal year, mainly through proceeds from the issuance of shares upon the exercise of stock acquisition rights. - FY2021-Q3AdvancedAnnual report
「1 February 2021–30 April 2021 (Note) 426,000 58,802,700 1,617 26,416 1,617 10,494,400 (Note) Increase due to the exercise of stock acquisition rights.」
The exercise of stock acquisition rights resulted in the issuance of 426,000 shares and an increase of ¥1.617 million each in capital stock and the capital reserve. - FY2021-Q2AdvancedAnnual report
「Funds provided by financing activities during the six-month period amounted to ¥95.568 million, compared with proceeds of ¥7,720.776 million in the same period of the previous year. This was mainly attributable to proceeds of ¥97.049 million from the issuance of shares.」
The company raised ¥97.049 million through the issuance of shares and generated ¥95.568 million in financing funds during the six-month period. - FY2020AdvancedAnnual report
「Funds provided by financing activities amounted to ¥7,757.140 million, compared with proceeds of ¥1,437.374 million in the previous fiscal year. This was mainly attributable to proceeds from the issuance of shares in connection with the listing on the Mothers market of the Tokyo Stock Exchange.」
The company raised ¥7,757.14 million in financing funds during the fiscal year, mainly through the issuance of shares accompanying the listing. - FY2020-Q3RestatedAnnual report
「In addition, funds raised through the public offering accompanying the new listing enabled us to further increase investment in this project and establish a foundation for accelerating research and development.」
The explanation that the public offering accompanying the new listing would provide the foundation for research and development investment is being reiterated. - FY2020-Q2RestatedAnnual report
「Funds provided by financing activities during the six-month period amounted to ¥7,720.776 million. This was mainly attributable to proceeds of ¥7,731.581 million from the issuance of shares, offset by ¥9.363 million in listing-related expenses.」
The funds raised through the issuance of shares accompanying the new listing and the resulting strengthening of the cash position and financial base supporting research and development are being reaffirmed with amounts. - FY2020-Q1AdvancedAnnual report
「Total current assets at the end of the first quarter of the current fiscal year amounted to ¥10,161.623 million, an increase of ¥7,492.543 million from the end of the previous fiscal year. This was mainly due to an increase of ¥7,521.337 million in cash and deposits.」
Cash and deposits increased by ¥7,521.337 million, mainly as a result of the public offering accompanying the August 2019 new listing, strengthening the financial base for research and development investment. - FY2019First statedAnnual report
「We believe that an important management priority for the company going forward is to strengthen and stabilise its financial base as necessary by raising funds from investors, including venture capital firms, and from the capital markets through share issuance.」
The company anticipates raising funds from investors and through share issuance to continue investing in research and development.